1. Home
  2. DFNS vs LGVN Comparison

DFNS vs LGVN Comparison

Compare DFNS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFNS

T3 Defense Inc. Common Stock

N/A

Current Price

$37.95

Market Cap

27.2M

ML Signal

N/A

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.77

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFNS
LGVN
Founded
2013
2014
Country
United States
United States
Employees
15
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
25.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DFNS
LGVN
Price
$37.95
$0.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
23.3M
220.5K
Earning Date
04-09-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.48
52 Week High
$91.00
$1.23

Technical Indicators

Market Signals
Indicator
DFNS
LGVN
Relative Strength Index (RSI) 58.90 65.31
Support Level $0.30 $0.60
Resistance Level $91.00 $0.87
Average True Range (ATR) 13.65 0.05
MACD 3.10 0.02
Stochastic Oscillator 49.58 88.22

Price Performance

Historical Comparison
DFNS
LGVN

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: